510(k) K252424
K252424 is an FDA 510(k) premarket notification submitted by Abbott Laboratories for the device "Anti-HCV Next". The FDA issued a decision of Substantially Equivalent on April 28, 2026. The device falls under product code MZO (Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus), a Class II device regulated under 21 CFR 866.3169. Abbott Laboratories has at least 10 other 510(k) clearances on record.
Clearance Details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- April 28, 2026
- Date Received
- August 1, 2025
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device Classification
- Device Name
- Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus
- Device Class
- Class II
- Regulation Number
- 866.3169
- Review Panel
- MI
- Submission Type